References
- GLOBOCAN Cancer Fact Sheets: liver Cancers [Internet]. [cited 2017 Apr 2]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp.
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics. 2012. CA Cancer J Clin [Internet]. 2015;65:87–108.
- Davila JA, El-Serag H. 458 The rising incidence of hepatocellular carcinoma in the United States: an update. Gastroenterology [Internet]. 2012;142:S–914. Available from http://linkinghub.elsevier.com/retrieve/pii/S0016508512635495
- Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30.
- Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet [Internet]. 2015;385:977–1010.
- Zhang B-H, Yang B-H, Tang Z-Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol [Internet]. 2004;130:417–422. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15042359
- European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol [Internet]. 2012;56:908–943. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22424438
- Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:5–16.
- Yip B, Ha NB, Kim LH, et al. 460 ethnic differences in clinical characteristics and treatments of Asian and Non-Asian with hepatitis C (HCV)-related hepatocellular carcinoma (HCC). Gastroenterology [Internet]. 2012;142:S-914-S-915. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508512635513
- Ibrahim AS, Khaled HM, Mikhail NN, et al. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. [Internet]. 2014;2014:1–18. Available from: http://www.hindawi.com/journals/jce/2014/437971/
- Yang JD, Mohamad EA, Aziz AOA, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol [Internet]. 2017;2:103–111. Available from: http://www.journals.elsevier.com/the-lancet-gastroenterology-and-hepatology%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed18b&NEWS=N&AN=614403322
- Omar A, Abou-Alfa GK, Khairy A, et al. Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol [Internet]. 2013;2:43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25841922
- Fitzmorris P, Shoreibah M, Anand BS, et al. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141:861–876.
- Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, et al. Diagnosis and treatment of hepatocellular carcinoma: an update. World J Hepatol. 2015;7:362–376.
- Sorafenib Tosylate Monograph for Professionals - Drugs.com [Internet]. [cited 2017 May 12]. Available from: https://www.drugs.com/monograph/sorafenib-tosylate.html.
- Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–4300.
- Llovet JM, Mazzaferro V, Hilgard P, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
- Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol Internet. 2009:10:25–34. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L50365562%5Cn.
- Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology Internet. 2016;150:836–853.
- Peixoto RD, Renouf DJ, Gill S, et al. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol [Internet]. 2014;5:259–264. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25083298%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4110502
- Kudo M, Lencioni R, Marrero JA, et al. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int. 2016;36:1196–1205.
- Abraham A, Purushothaman C, Damien D, et al. Efficacy of sorafenib therapy in patients with advanced hepatocellular carcinoma in Indian population. Hepatoma Res [Internet]. 2016;2:224. Available from: http://hrjournal.net/article/view/1644
- Abdel-Rahman O, Abdelwahab M, Shaker M, et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egypt Natl Canc Inst Internet. 2014;26:9–13. Available from.
- Hassan ZK, Hafez MM, Mansor TM, et al. Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J. 2011;8:90.
- Zekri ARN, Bahnassy A, Madbouly MS, et al. p53 mutation in HCV-genotype-4 associated hepatocellular carcinoma in Egyptian patients. J Egypt Natl Canc Inst. 2006;18:17–29.
- Zekri ARN, Hma E-D, Bahnassy AA, et al. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virol J [Internet]. 2007;4:16. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1805740&tool=pmcentrez&rendertype=abstract
- Zekri ARN, Hassan ZK, Bahnassy AA, et al. Molecular prognostic profile of egyptian HCC cases infected with hepatitis C virus. Asian Pacific J Cancer Prev. 2012;13:5433–5438.
- Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
- Nexavar Monograph for Professionals - Drugs.com [Internet]. [cited 2017 May 31]. Available from: https://www.drugs.com/monograph/nexavar.html.
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;1:52–60.
- Sanoff HK, Chang Y, Lund JL, et al. Sorafenib effectiveness in advanced hepatocellular carcinoma. [cited 2017 Jul 7]; Available from: http://theoncologist.alphamedpress.org/content/21/9/1113.full.pdf.
- Final results of the GIDEON (Global Investigational of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study according to patient | oncologyPRO [Internet]. cited 2017 May 11. Available from: http://oncologypro.esmo.org/Meeting-Resources/WorldGI-2015/Final-results-of-the-GIDEON-Global-Investigational-of-therapeutic-DEcisions-in-HCC-and-Of-its-treatment-with-sorafeNib-study-according-to-patient-etiology-The-Italian-experience.
- Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68:609–617.
- Pressiani T, Boni C, Rimassa L, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol. 2013;24:406–411.
- Abdelmabood A, Salem SE, Mahmoud M, et al. Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma. 2015;2:3–9.
- Zekri AA-RN, Hafez MM, Bahnassy AA, et al. Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: preliminary study. BMC Res Notes [Internet]. 2008;1:106. Available from: http://www.biomedcentral.com/1756-0500/1/106%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2584108&tool=pmcentrez&rendertype=abstract%5Cnhttp://www.biomedcentral.com/1756-0500/1/106/
- Pollutri D, Gramantieri L, Bolondi L, et al. TP53/MicroRNA interplay in hepatocellular carcinoma. Int J Mol Sci. 2016;17:1–20.
- Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer. 2009;124:690–697.
- Hsiao W-D, Peng C-Y, Chuang P-H, et al. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterol [Internet]. 2016;16:50. Available from.
- Cammà C, Cabibbo G, Petta S, et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology. 2013;57:1046–1054.
- Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib: case report. Am J Transplant. 2009;9:2851–2854.
- So BJ, Bekaii-Saab T, Bloomston MA, et al. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol [Internet]. 2008;1:18. Available from: http://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-1-18
- Report CAC. JOURNAL OF CLINICAL ONCOLOGY Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular. 2014;29:330–332.
- Lee Y, Kim BH, Kim BC, et al. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget. 2015;6(18):16449–16460.
- Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Internet. 2016;0:1020–1022. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673616324539
- Wang P, Tan G, Zhu M, et al. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol [Internet]. 2017;4124:1–8.
- Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155–2166.
- Palmer DH, Hussain SA, Smith AJ, et al. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. Br J Cancer [Internet]. 2013;109:888–890. Available from.